16 research outputs found
Role of liraglutide in Alzheimer's disease pathology
Background The described relationship between Alzheimer's disease (AD) and type 2 diabetes (T2D) and the fact that AD has no succesful treatment has led to the study of antidiabetic drugs that may limit or slow down AD pathology. Main body Although T2D treatment has evident limitations, options are increasing including glucagon-like peptide 1 analogs. Among these, liraglutide (LRGT) is commonly used by T2D patients to improve beta cell function and suppress glucagon to restore normoglycaemia. Interestingly, LRGT also counterbalances altered brain metabolism and has anti-inflammatory properties. Previous studies have reported its capacity to reduce AD pathology, including amyloid production and deposition, tau hyperphosphorylation, or neuronal and synaptic loss in animal models of AD, accompanied by cognitive improvement. Given the beneficial effects of LRGT at central level, studies in patients have been carried out, showing modest beneficial effects. At present, the ELAD trial (Evaluating Liraglutide in Alzheimer's Disease NCT01843075) is an ongoing phase IIb study in patients with mild AD. In this minireview, we resume the outcomes of LRGT treatment in preclinical models of AD as well as the available results in patients up to date. Conclusion The effects of LRGT on animal models show significant benefits in AD pathology and cognitive impairment. While studies in patients are limited, ongoing clinical trials will probably provide more definitive conclusions on the role of LRGT in AD patients
Due mostre: “Architettura Contemporanea In Brasile. Panorama Da Arquitetura Brasileira” e “Un’Architettura Rivoluzionaria In Uruguay. Omaggio A Eladio Dieste”
Allestimento e componente della segreteria scientifica per le due mostre di architettura esposte negli spazi espositivi della FacoltĂ di Architettura di Pescara dal 23 al 26/06/2008
Is Alexithymia a CV Risk Factor in Healthy Adults?
Background: We investigated whether alexithymia is associated with cardiometabolic risk factors (RF) and increased CVD risk. Methods: 1,170 adult blood donors (74.8% males, aged 46.1±10.0) were recruited and assessed for traditional, biochemical and lifestyle RF. Psychological factors, including alexithymia (TAS-20) and depressive symptoms (BDI-II) were concurrently assessed. We evaluated CVD risk according to Framingham risk score (FRS) and Italian NIH (National Institute of Health) CUORE risk score (CRS). Estimated 10-year CVD risk was calculated with both scores. Results: The prevalence of moderate-to-high risk was 13% (FRS) and 21% (CRS). The alexithymic group (23.6%) had significantly a lower education and occupational status, as well as higher BMI, higher total and LDL cholesterol, higher lipoprotein-a, and depression score than the non-alexithymic group. Consistently, the percentage of subjects at moderate-tohigh CVD risk was significantly higher in the alexithymic group for both FRS and CRS. A stepwise forward multivariate logistic regression was used to select predictors of moderateto-high CVD risk. The results showed that alexithymia was a strong independent predictor of increased estimated CVD risk at 10 years for both FRS (OR: 2.40; 95% CI: 1.38-4.14; p=0.002) and CRS (OR: 2.11; 95% CI: 1.32-3.38; p=0.002), after adjustment for sociodemographic and lifestyle factors, BMI, diastolic blood pressure, metabolic RF (fasting blood glucose, LDL and triglycerides), and biochemical RF.
Conclusions: This large cohort study suggests that alexithymia may be considered a major psychological factor for CVD risk in healthy population. Longitudinal studies are needed for investigating the role of alexithymia in clinical outcomes (morbidity and mortality)
Olio su lucido (Concorso di Progettazione in due fasi Premio Tercas Architettura XIII Edizione_progetto secondo classificato)
Progetto e relazione delle due fasi di consors
Alexithymia Predicts Carotid Atherosclerosis, Vascular Events, and All-Cause Mortality in Human Immunodeficiency Virus-Infected Patients: An Italian Multisite Prospective Cohort Study
Background: Psychological factors (PFs) are known predictors of cardiovascular disease (CVD) in many clinical settings, but data are lacking for human immunodeficiency virus (HIV) infection. We carried out a prospective study to evaluate (1) psychological predictors of preclinical and clinical vascular disease and (2) all-cause mortality (ACM) in HIV patients. Methods: We conducted a cross-sectional analysis of baseline data to evaluate the predictors of carotid plaques (CPs) and a prospective analysis to explore predictors of vascular events (VEs) and ACM over 10 years. Human immunodeficiency virus patients monitored at the Infectious Disease Units of 6 Italian regions were consecutively enrolled. Traditional CVD risk factors, PFs (depressive symptoms, alexithymia, distress personality), and CPs were investigated. Vascular events and ACM after enrollment were censored at March 2018. Results: A multicenter cohort of 712 HIV-positive patients (75.3% males, aged 46.1 ± 10.1 years) was recruited. One hundred seventy-five (31.6%) patients had CPs at baseline. At the cross-sectional analysis, alexithymia was independently associated with CPs (odds ratio, 4.93; 95% confidence interval [CI], 2.90-8.50; P <. 001), after adjustment for sociodemographic, clinical, and psychological variables. After an average follow-up of 4.4 ± 2.4 years, 54 (7.6%) patients developed a VE, whereas 41 (5.68%) died. Age, current smoking, hypertension, and alexithymia (hazard ratio [HR], 3.66; 95% CI, 1.80-7.44; P <. 001) were independent predictors of VE. Likewise, alexithymia was an independent predictor of ACM (HR, 3.93; 95% CI, 1.65-9.0; P =. 002), regardless of other clinical predictors. Conclusions: The present results validate our previous monocentric finding. Alexithymia may be an additional tool for the multifactorial assessment of cardiovascular risk in HIV
et al. Atherosclerosis, vascular events and dementia risk in HIV-infected patients. Preliminary data from the Italian multicentre cohort of the Cardiovascular and late-life dementia risk in HIV (CARDH) Study.
CittĂ parco ardeatina/167 (Paesaggi Costieri, Concorso Internazionale di Progettazione e Fotografia, Comune di Ardea, Legambiente, Ministero per i Beni e le AttivitĂ Culturali_progetto con secondo premio "Selezione")
Progetto di concorso e relazion